Page 30 - Patent News Today

The America Invents Act ("AIA") bars a person from obtaining a patent when the "claimed invention" had been "on sale" more than one year before the filing date of the patent. 35 U.S.C. § 102(a)(1).

The USPTO issued a patent to NAPIGEN for the use of CRISPR technologies to edit organellar genomes. Separately, USDA awarded NAPIGEN an SBIR phase 1...

Packet Intelligence LLC v. NetScout Systems, Inc., No. 22-2064, Courtroom 402, Panel B Packet Intelligence LLC ("Packet Intelligence") asserted U.S. Patent No. 6,954,789...

The Federal Circuit's decision in University of South Florida Board of Trustees v. United States, 22-2248 (Fed. Cir. Feb. 9, 2024) hints at the broad scope of the federal government's license rights under the Bayh-Dole Act.

A few days ago, The Wall Street Journal reported on its readers' views on copyright and other legal issues related to artificial intelligence (AI).

On January 28, 2024 Celltrion announced the submission to the FDA of an aBLA for CT-P47, a proposed biosimilar of Genentech's Actemra® (tocilizumab).

On February 14, 2024, Seagen requested director review of the PTAB's January 16th Final Written Decision ("FWD") in PGR2021-00030 finding antibody-drug conjugate claims in U.S. Patent No. 10,808,039...

Late last month, a Patent Trial and Appeal Board ("PTAB") panel instituted two petitions that were filed separately by Celltrion and Biocon for inter partes review ("IPR") of Regeneron's U.S.

Due to the quick rise of artificial intelligence (AI), most (if not all) of the laws relating to the US patent system were not written with AI in mind. Court precedent...

Intellectual property ("IP") is hugely important to businesses. Given that importance, IP owners must occasionally litigate against the unauthorized use of their technology.